Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, 2-period, Placebo-controlled, Single-center, Crossover Study to Assess the Therapeutic Equivalence of the EMLA Current Reference Patch and the EMLA Test Patch in Healthy Subjects.

NCT03313336 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03313336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03313336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, 2-period, Placebo-controlled, Single-center, Crossover Study to Assess the Therapeutic Equivalence of the EMLA Current Reference Patch and the EMLA Test Patch in Healthy Subjects.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 30, 2017
Completion date
November 9, 2017
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain